127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-10-02T10:57:03Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 2 octombrie 2024 13:57
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Novus Therapeutics, Inc. (novustherapeutics.com) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device combination product being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media (“OM” or middle ear inflammation with or without infection). Globally, OM affects more than 700 million adults and children every year, with over half of the cases occurring in children under five years of age. OM is one of the most common disorders seen in pediatric practice, and in the United States is a leading cause of health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Novus also has a foam-based drug delivery technology (OP0102), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.		Novus Therapeutics, Inc. (novustherapeutics.com) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device combination product being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media (“OM” or middle ear inflammation with or without infection). Globally, OM affects more than 700 million adults and children every year, with over half of the cases occurring in children under five years of age. OM is [[one]] of the most common disorders seen in pediatric practice, and in the United States is a leading cause of health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Novus also has a foam-based drug delivery technology (OP0102), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Novus Therapeutics, Inc. listata cu simbolul US.NVUS ==Descriere companie== Novus Therapeutics, Inc. (novustherapeutics.com) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device combination...

2024-09-18T18:17:33Z

Pagină nouă: Pagina dedicata companiei Novus Therapeutics, Inc. listata cu simbolul US.NVUS ==Descriere companie== Novus Therapeutics, Inc. (novustherapeutics.com) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device combination...

Pagină nouă

Pagina dedicata companiei Novus Therapeutics, Inc. listata cu simbolul US.NVUS

==Descriere companie==
Novus Therapeutics, Inc. (novustherapeutics.com) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device combination product being developed as a potential first-in-class treatment option for patients at risk for, or with, otitis media (“OM” or middle ear inflammation with or without infection). Globally, OM affects more than 700 million adults and children every year, with over half of the cases occurring in children under five years of age. OM is one of the most common disorders seen in pediatric practice, and in the United States is a leading cause of health care visits and the most frequent reason children are prescribed antibiotics or undergo surgery. Novus also has a foam-based drug delivery technology (OP0102), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.NVUS" />

==Ultimele stiri despre Novus Therapeutics, Inc. (US.NVUS)==
<dynamicpagelist>
category=US.NVUS
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.NVUS]][[Categorie:Stiri despre companii]]

Novus Therapeutics, Inc. - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).